Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ADMS Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Adamas Pharmaceuticals Stock (NASDAQ:ADMS) 30 days 90 days 365 days Advanced Chart Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Adamas Pharmaceuticals alerts:Sign Up Key Stats Today's Range$8.22▼$8.2250-Day Range$7.97▼$8.2352-Week Range$4.02▼$9.15VolumeN/AAverage Volume692,487 shsMarket Capitalization$376.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Read More… JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Receive ADMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMS Stock News HeadlinesWhy did the Raiders trade Davante Adams? Drama, contract lead to Jets dealOctober 16, 2024 | usatoday.comGlancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMSMay 13, 2024 | prnewswire.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 17, 2024 | Colonial Metals (Ad)Survalent, Electroval win bid to provide ICE "first of its kind" ADMS and DERMS platformApril 7, 2023 | benzinga.comAdvanced Distribution Management Systems (ADMS) Market 2023 | Global Industry Report Forecast 2029April 7, 2023 | marketwatch.comAdvanced Distribution Management Systems (ADMS) Market LATEST REPORT 2023 to 2030March 30, 2023 | marketwatch.comAdamas One Corp (JEWL)March 3, 2023 | investing.com2023 Advanced Distribution Management System (ADMS) Market: Top Growing Regions for Business Leaders by 2029March 1, 2023 | marketwatch.comSee More Headlines ADMS Stock Analysis - Frequently Asked Questions How were Adamas Pharmaceuticals' earnings last quarter? Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to analyst estimates of $25.07 million. What other stocks do shareholders of Adamas Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adamas Pharmaceuticals investors own include Rite Aid (RAD), VBI Vaccines (VBIV), Amarin (AMRN), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Exelixis (EXEL). Company Calendar Last Earnings11/11/2021Today11/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADMS CUSIPN/A CIK1328143 Webwww.adamaspharma.com Phone(510) 450-3500Fax510-428-0519Employees138Year Founded2002Profitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,400,000.00 Net Margins-71.11% Pretax Margin-71.11% Return on EquityN/A Return on Assets-42.96% Debt Debt-to-Equity Ratio21.25 Current Ratio4.53 Quick Ratio4.17 Sales & Book Value Annual Sales$74.46 million Price / Sales5.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-17.49Miscellaneous Outstanding Shares45,787,000Free Float37,133,000Market Cap$376.37 million OptionableOptionable Beta2.82 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ADMS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamas Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adamas Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADMS Stock Alerts